Current stock page

Catalysts

VRNA Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Sep 7, 2026

VRNA

Catalysts
Verona Pharma plc
Healthcare· Biotechnology
AIQ Score
NeutralAIQ Edge 2/10
Low Priority
Relative Laggard
Score data as of Sep 7, 2026
Last price
Latest market quote
Momentum
Value34
Quality47
Risk Resilience54
Sentiment
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings

No upcoming reporting date is available yet.

AIQ Catalyst
AIQ 43/100

Momentum and sentiment before the next covered event.

Recent coverage
4 articles

Updated Sep 6, 2026 · Sentiment 30.71%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum AIQ Edge 2/10 Relative Laggard
Beat rate
38%
3 of 8 reported periods
Average surprise
+101.8%
Across covered historical reports
Latest result
-450.0%
Nov 3, 2025
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 3, 2025$0.16-$0.56-450.0%
Aug 7, 2025-$0.01$0.13+1400.0%$95.37M$97.89M
Apr 29, 2025-$0.22$0.27+222.7%$53.36M$76.26M
Feb 27, 2025-$0.23-$0.40-73.9%$33.04M$36.66M
Nov 4, 2024-$0.50-$0.56-12.0%$2.02M$5.62M
Aug 8, 2024-$0.29-$0.88-203.4%$2.01M
May 9, 2024-$0.16-$0.32-100.0%
Feb 29, 2024-$0.26-$0.18+30.8%

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Hold
1
Buy
10
Hold
12-month analyst target
$107.00
versus current price
Based on 1 analyst observations. Targets are estimates, not predictions.
Low target
$107.00
Average target
$107.00
High target
$107.00

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event date

Upcoming earnings date not available yet.

Sentiment score

News pressure around the setup.

Momentum score

Where event reaction would show up first.

AIQ score43/100

Composite decision read before event confirmation.

Analyst context

Consensus
Hold
Analysts
1
Average target
$107.00
Target range
$107.00 - $107.00
90-day revisions
0

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
1
Negative
0
finance.yahoo.com · Aug 18, 2026

Fulcrum and Slate Medicines sign merger agreement

After completion of the merger, the combined company will develop Slate’s migraine treatment pipeline.

manilatimes.net · Aug 17, 2026

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics

manilatimes.net · Aug 11, 2026

Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27

manilatimes.net · Aug 11, 2026

Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval

Open full news and sentiment

VRNA Catalysts FAQ

What are the next catalysts for VRNA stock?

VRNA's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move VRNA stock?

Upcoming events that could move VRNA include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could VRNA's next earnings report affect the stock?

VRNA's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive VRNA stock higher?

VRNA could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt VRNA stock?

VRNA could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.